It is one of the seven public hospitals in the region that are part of the National Network of centers authorized by the Ministry of Health for these advanced therapies.
This cellular immunotherapy has been tested in patients with CD30+ lymphomas (Hodgkin’s and T lymphomas) refractory to brentuximab vedotin.
Editor-in-Chief Prize-winning journalist with over 20 years of international news experience. Alexandra leads the editorial team, ensuring every story meets the highest standards of accuracy and journalistic integrity.
